undamentalytics Newsletter
Sign in

Emergent Biosolutions Inc. balance sheet

At the end of fiscal 2025, Emergent Biosolutions Inc. had total assets of $1.32bn, total liabilities of $796m and shareholders' equity of $523m. It held $205m in cash against $590m of debt: net debt of $384m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents103169144142179280313272178112168621576643112100205176
Receivables—39749661591141381442632712312791591911558478
Inventory—13151515666174143206223307345351329312343281
Total current assets—2432542632734325375104856216861,1961,2701,210680599663558
Goodwill—6661453414149260267267225218000—
Total assets—5005475646279391,0379701,0702,2292,3272,8832,9583,1661,8231,3901,319995
Accounts payable—25413128413835428195136129104112615652
Deferred revenue (current)—812254713113451226275514
Total current liabilities—76716257931001061002002163853741,229651162132122
Short-term debt—17540———0101334329574140——
Long-term debt—3054586225124724814785798841809449447664572508
Total debt047596362251247268148198359198811,406860700590514
Total liabilities—1271301221373853773741581,2191,2391,4361,3461,7791,174907796682
Shareholders' equity2443694144414905536605969121,0111,0911,4511,6121,388649483523313
Net debt (negative = net cash)−103−122−84−79−117−29−66−3−165707668298305763749601384339
Shares outstanding—35m36m36m37m38m39m41m49m51m52m53m51m50m52m54m52m51m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: EBS vs TVTXALVO vs EBSAMPH vs EBS

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Emergent Biosolutions Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Emergent Biosolutions Inc.